94 related articles for article (PubMed ID: 10568160)
1. [Activated protein C resistance of an acquired nature: the potential role of hormonal treatment and of elevated factor VIII plasma levels].
Iturbe Hernández T; Varo MJ; Olave MT; Fuertes MA; Cornudella R
Rev Clin Esp; 1999 Sep; 199(9):618. PubMed ID: 10568160
[No Abstract] [Full Text] [Related]
2. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
[TBL] [Abstract][Full Text] [Related]
3. Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Raps M; Curvers J; Helmerhorst FM; Ballieux BE; Rosing J; Thomassen S; Rosendaal FR; van Vliet HA
Thromb Res; 2014 Apr; 133(4):640-4. PubMed ID: 24438944
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Olsson E; Höijer P
Br J Plast Surg; 2005 Jul; 58(5):720-3. PubMed ID: 15992531
[TBL] [Abstract][Full Text] [Related]
5. Changes of hemostatic variables during oral contraceptive use.
Tans G; Bouma BN; Büller HR; Rosing J
Semin Vasc Med; 2003 Feb; 3(1):61-8. PubMed ID: 15199493
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
7. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
[TBL] [Abstract][Full Text] [Related]
8. [Oral contraceptives and activated protein C resistance: a paradigmatic example of genotype and environment interaction in the development of deep venous thrombosis].
Panzini E; Raffa S; Miconi R; Lozzi A; Marci M
Clin Ter; 1999; 150(6):445-7. PubMed ID: 10756665
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
[TBL] [Abstract][Full Text] [Related]
10. [Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study].
Canonico M; Scarabin PY
Med Sci (Paris); 2008 Mar; 24(3):228-31. PubMed ID: 18334161
[No Abstract] [Full Text] [Related]
11. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
12. Cardiology patient page. Factor V Leiden.
Ornstein DL; Cushman M
Circulation; 2003 Apr; 107(15):e94-7. PubMed ID: 12707252
[No Abstract] [Full Text] [Related]
13. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J
Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335
[TBL] [Abstract][Full Text] [Related]
15. [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
Caserta L; Caserta R; Torella M; Perricone F; Nesti E; Sessa M; Tagliaferri A; De Francesco F; De Lucia D; Panariello S
Minerva Ginecol; 2004 Apr; 56(2):131-6. PubMed ID: 15258541
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cell activation and hypercoagulability in ocular Behçet's disease.
Probst K; Fijnheer R; Rothova A
Am J Ophthalmol; 2004 May; 137(5):850-7. PubMed ID: 15126149
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C.
De Mitrio V; Marino R; Cicinelli E; Galantino P; Di Bari L; Giannoccaro F; De Pergola G; Lapecorella M; Schonauer S; Schiraldi O
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):175-82. PubMed ID: 10759011
[TBL] [Abstract][Full Text] [Related]
18. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of factor VIII:C, oral contraceptives and thrombosis: report of a case.
Faricciotti A; Bucciarelli P; Vismara A; Porro T; Guariglia A; Castelli R
Haematologica; 2002 May; 87(5):ECR18. PubMed ID: 12010681
[No Abstract] [Full Text] [Related]
20. APC resistance, oral contraceptive therapy and deep vein thrombosis: settled and unsettled problems.
Girolami A; Simioni P; Tormene D
Haematologica; 2000 Mar; 85(3):225-6. PubMed ID: 10702806
[No Abstract] [Full Text] [Related]
[Next] [New Search]
